Pressreleaser | 11 Jul 2023 | Intervacc

Intervacc to collaborate with Testa Center to optimise production processes for their prototype vaccine for pigs

Intervacc’s innovative vaccine technology involves fusing important proteins together in order to protect animals from complex bacterial diseases. The new pig vaccine generated positive results in early proof-of-concept studies where the consumption of colostrum from vaccinated sows provided significant levels of protection to piglets at 4 and 7 weeks of age against meningitis, septicaemia and arthritis following challenge with a virulent strain of Streptococcus suis.

Testa Center provide businesses with a modern, pilot-scale testbed to optimise the scale-up processes required to manufacture biologics. The new ”on-boarding” project provides a grant to Intervacc of about 118 kSEK, which represents 50% of the ”on-boarding” costs for this project that aims to optimise the laboratory-scale production of a recombinant fusion protein in the vaccine in preparation for its transfer to the small-scale production facilities at Testa Center.

”We are delighted to be working with Testa Center to develop the processes required to optimise the production of our prototype vaccine prior to scaling-up,” commented Dr. Andrew Waller, CSO of Intervacc, ”Streptococcus suis causes serious infections in piglets throughout the world leading to significant costs to the industry. A safe and effective vaccine is urgently required to spare piglets from the suffering caused, boost production and decrease the requirement to treat this disease with antimicrobial agents.”

”Testa Center welcomes all innovative solutions that have the potential to create new technological advances that prevent disease. Our staff and facilities are dedicated to help companies to bridge the gap from discovery to industrialisation,” said Dr. Jesper Hedberg, CEO of Testa Center. ”This new project with Intervacc will optimise the first steps in the manufacturing processes towards producing the prototype vaccine at a scale and quality suitable for further testing.”

For more information please contact:

Andreas Andersson, CEO

Phone: +46-8-120 10 601, cell +46-73-335 99 70
E-mail: andreas.andersson@intervacc.com

The information was submitted for publication, through the agency of the contact person set out above on July 11, 2023, 09.30 CET.

About Intervacc

Intervacc AB is a Swedish company within animal health developing vaccines for animals. The Company’s vaccine and vaccine candidates are based on several years of research at Karolinska Institutet and Swedish University of Agricultural Research where the foundation was laid for the Company’s research and development work. The Intervacc share has been listed on the Nasdaq First North Growth Market since April 2017 with Eminova Fondkommission AB as Certified Adviser.

About Testa Center

Testa Center is a non-profit company byCytiva ( http://www.cytiva.com/ ), formerly GE Healthcare. Co-founded in 2018 by the Swedish agency for innovation,Vinnova ( https://vinnova.se/ ), for thegrowth of the life science industry and its manufacturing capabilities ( https://nordiclifescience.org/testa-center-1-year-accelerating-time-to-clinical-trials/ ).

Contact information for Certified Adviser

Eminova Fondkommission AB

E-mail: adviser@eminova.se,Phone: +46 (0)8 – 684 211 10